Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin

Neuroscience Letters

Volumn 563, Issue , 2014, Pages 123-128

  Murata, Yui ^a   Nishioka, Masaki ^a   Bundo, Miki ^a   Sunaga, Fumiko ^a   Kasai, Kiyoto ^a   Iwamoto, Kazuya ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antipsychotic drug; Blonanserin; DNA methylation; Human neuroblastoma cell

Indexed keywords

ANTIPSYCHOTIC DRUG; BLONANSERIN; DNA METHYLATION; HUMAN NEUROBLASTOMA CELL;

ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOME, HUMAN; HUMANS; NEUROBLASTOMA; PIPERAZINES; PIPERIDINES;

EID: 84894091072     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.01.038     Document Type: Article

References (20)

1. Asai T., Bundo M., Sugawara H., Sunaga F., Ueda J., Tanaka G., Ishigooka J., Kasai K., Kato T., Iwamoto K. Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int. J. Neuropsychopharmacol. 2013, 1-10.
2. Bigos K.L., Mattay V.S., Callicott J.H., Straub R.E., Vakkalanka R., Kolachana B., Hyde T.M., Lipska B.K., Kleinman J.E., Weinberger D.R. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch. Gen. Psychiat. 2010, 67:939-945.
3. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
4. Dedeurwaerder S., Defrance M., Calonne E., Denis H., Sotiriou C., Fuks F. Evaluation of the Infinium Methylation 450K technology. Epigenomics 2011, 3:771-784.
5. Dempster E., Viana J., Pidsley R., Mill J. Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schiz. Bull. 2013, 39:11-16.
6. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID. database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
7. Erk S., Meyer-Lindenberg A., Schnell K., Opitz von Boberfeld C., Esslinger C., Kirsch P., Grimm O., Arnold C., Haddad L., Witt S.H., Cichon S., Nöthen M.M., Rietschel M., Walter H. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch. Gen. Psychiat. 2010, 67:803-811.
8. Ferreira M.A., O'Donovan M.C., Meng Y.A., Jones I.R., Ruderfer D.M., Jones L., Fan J., Kirov G., Perlis R.H., Green E.K., Smoller J.W., Grozeva D., Stone J., Nikolov I., Chambert K., Hamshere M.L., Nimgaonkar V.L., Moskvina V., Thase M.E., Caesar S., Sachs G.S., Franklin J., Gordon-Smith K., Ardlie K.G., Gabriel S.B., Fraser C., Blumenstiel B., Defelice M., Breen G., Gill M., Morris D.W., Elkin A., Muir W.J., McGhee K.A., Williamson R., MacIntyre D.J., MacLean A.W., St Clair D., Robinson M., Vanbeck M., Pereria A.C., Kandaswamy R., McQuillin A., Collier D.A., Bass N.J., Young A.H., Lawrence J., Ferrier I.N., Anjorin A., Farmer A., Curtis D., Scolnick E.M., McGuffin P., Daly M.J., Corvin A.P., Holmans P.A., Blackwood D.H., Wellcome Trust Case Control Consortium, Gurling H.M., Owen M.J., Purcell S.M., Sklar P., Craddock N. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 2008, 40:1056-1058.
9. Franke B., Vasquez A.A., Veltman J.A., Brunner H.G., Rijpkema M., Fernandez G. Genetic variation in CACNA1C, a gene associated with bipolar disorder, influences brainstem rather than gray matter volume in healthy individuals. Biol. Psychiat. 2010, 68:586-588.
10. Hulsen T., de Vlieg J., Alkema W. BioVenn - a web application for the comparison and visualization of biological lists using area-proportional venn diagrams. BMC Genomics 2008, 9:488.
11. Kempton M.J., Ruberto G., Vassos E., Tatarelli R., Girardi P., Collier D., Frangou S. Effects of the CACNA1C risk allele for bipolar disorder on cerebral gray matter volume in healthy individuals. Am. J. Psychiat. 2009, 166:1413-1414.
12. Kishi T., Matsuda Y., Nakamura H., Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J. Psychiat. Res. 2013, 47:149-154.
13. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzâlez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 2012, 15:1245-1254.
14. Nishioka M., Bundo M., Kasai K., Iwamoto K. DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Med. 2012, 4:96.
15. Nishioka M., Bundo M., Koike S., Takizawa R., Kakiuchi C., Araki T., Kasai K., Iwamoto K. Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J. Hum. Genet. 2013, 58:91-97.
16. Psychiatric GWAS consortium bipolar disorder working group, Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4, Nature genetics 43 (2011) 977-983.
17. Rajakulendran S., Kaski D., Hanna M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS, nature reviews. Neurology 2012, 8:86-96.
18. Schizophrenia psychiatric genome-wide association study (GWAS) consortium, genome-wide association study identifies five new schizophrenia loci, nature genetics 43 (2011) 969-976.
19. Tenjin T., Miyamoto S., Miyake N., Ogino S., Kitajima R., Ojima K., Arai J., Teramoto H., Tsukahara S., Ito Y., Tadokoro M., Anai K., Funamoto Y., Kaneda Y., Sumiyoshi T., Yamacuchi N. Effect of blonanserin on cognitive function in antipsychotic-naive first-episode schizophrenia. Hum. Psychopharmacol. 2012, 27:90-100.
20. Yap Y.L., Lam D.C., Luc G., Zhang X.W., Hernandez D., Gras R., Wang E., Chiu S.W., Chung L.P., Lam W.K., Smith D.K., Minna J.D., Danchin A., Wong M.P. Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Res. 2005, 33:409-421.